Suchergebnisse - "Campbell, Paul"

PubPharm (384)

11

Identifying a stable and generalizable factor structure of major depressive disorder across three large longitudinal cohorts

enthalten in: Psychiatry research | 2024

von Tseng, V. | Tharp, J. | Reiter, J. | +105

12

Genomic variation in pepper vein yellows viruses in Australia, including a new putative variant, PeVYV-10

enthalten in: Archives of virology | 2024

von Filardo, F. | Nurulita, S. | Jones, L. | +4

13

Genomic variation in pepper vein yellows viruses in Australia, including a new putative variant, PeVYV-10

enthalten in: Archives of virology | 2024

von Filardo, F. | Nurulita, S. | Jones, L. | +4

14

Investigating the Association Between Nitrate Dosing and Nitrite Generation by the Human Oral Microbiota in Continuous Culture

enthalten in: bioRxiv.org | 2023

von Willmott, T. | Serrage, H. | Cottrell, E. | +4

15

Development of a rapid, accurate, and field deployable LAMP-CRISPR-Cas12a integrated assay for Xylella fastidiosa detection and surveillance

enthalten in: Australasian plant pathology | 2023

von Farrall, T. | Abeynayake, S. | Webster, W. | +5

16

Morphogenesis in Trypanosoma cruzi epimastigotes proceeds via a highly asymmetric cell division

enthalten in: PLoS neglected tropical diseases | 2023

von Campbell, P. | de Graffenried, C.

UpdateOf: bioRxiv. 2023 May 25;:. - PMID 37293088

17

Rapid Weight Loss Practices Within Olympic Weightlifters

enthalten in: Journal of strength and conditioning research | 2023

von Gee, T. | Campbell, P. | Bargh, M. | +1

18

A comparison of rapid weight loss practices within international, national and regional powerlifters

enthalten in: Nutrition and health | 2023

von Campbell, P. | Martin, D. | Bargh, M. | +1

19

Validation of extracorporeal membrane oxygenation mortality prediction and severity of illness scores in an international COVID-19 cohort

enthalten in: Artificial organs | 2023

von Shah, N. | Xue, B. | Xu, Z. | +107

20

Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II) : A Phase 2, Open-label, Randomised Controlled Trial

enthalten in: European urology | 2023

von Tan, W. | Prendergast, A. | Ackerman, C. | +16

CommentIn: Eur Urol. 2023 Feb;83(2):e56-e57. - PMID 36372625